RxDoctor Payments Data

Lisa Jantzen

Family · Hauppauge, NYNPI 1770896409

Payments from drug & device makers

$4,715in general payments, 2019–2025

Across 174 payments — averaging $27.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Boehringer Ingelheim$485
  • Lilly USA, LLC$416
  • Alkermes, Inc.$375
  • Pfizer$284
  • Novo Nordisk$282
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,703100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,715 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$91,121
Medicare patients
363
Services billed
1,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide15$19,628
OzempicSemaglutide13$13,538
SuboxoneBuprenorphine Hcl/Naloxone Hcl26$12,054
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl12$2,573
SynthroidLevothyroxine Sodium19$1,225
Albuterol Sulfate HfaAlbuterol Sulfate33$1,072
Atorvastatin Calcium112$844
Levothyroxine Sodium54$589
Olmesartan Medoxomil22$544
Metoprolol Succinate32$515
Losartan Potassium42$445
Ezetimibe16$433
Rosuvastatin Calcium52$420
Tamsulosin Hcl13$408
Omeprazole26$322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$416$19,62815 claims
Novo NordiskOzempic$282$13,53813 claims
Indivior Inc.Suboxone$170$12,05426 claims
AbbVieSynthroid$1,151$1,22519 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$55$58954 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.

Other family in Hauppauge

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →